MediPharm Labs Receives Canadian GMP Pharmaceutical Drug Establishment License

Pharmaceutical company MediPharm Labs Corp. LABS MEDIF MLZ has obtained Health Canada’s Drug Establishment Licence.

The permit, which is in accordance with the Food and Drugs Act and Regulations, will be utilized to confirm compliance with Good Manufacturing Practice standards.

It will allow the Barrie, Ontario-based company to conduct pharmaceutical manufacturing, testing, and sale of active pharmaceutical ingredients and pharmaceutical drug products that contain cannabis.

MediPharm said that DEL is “a first of its kind license” to produce cannabis issued in North America. In addition, it also allows the extraction of the cannabis plant and will enable the production of all cannabinoids, including MediPharm Labs GMP CBD isolate, which is >98% pure.

Apart from this permit, the company also holds the Australian TGA GMP certification.

The company noted that the permit allows the shipment of products from Canada to its global so-called business-to-business (B2B) customer base.

Keith Strachan, president and interim CEO of MediPharm Labs, said obtaining the DEL is a “great milestone.”

“This adds to our growing portfolio of advanced regulatory licenses globally. MediPharm Labs now becomes one of a small number of companies who can take cannabis plant material and produce an API or a pharmaceutical drug product that could have marketing authorization by regulatory bodies such as the European Medicines Agency and FDA,” Strachan added.

Earlier this month, MediPharm opted to extend its supply deal with Europe-based medical cannabis company ADREXpharma GmbH for an additional five years after entering into a private label sales agreement for exports to Europe with the German licensed distributor of medical cannabis and controlled drugs in 2019.

Photo by Andre Taissin on Unsplash

Market News and Data brought to you by Benzinga APIs
Posted In: CannabisGovernmentNewsPenny StocksRegulationsMarketsDrug Establishment LicenceHealth CanadaKeith Strachan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Benzinga Cannabis Capital Conference is coming to Florida

The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

Get your tickets now on – Prices will increase very soon!